MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Glutamate"

  • 2025 International Congress

    1H-NMR and UPLC/MS Metabolomics Identify Disrupted Homeostasis of Energy, Amino Acids, and Glutathione Metabolism as Serum Signatures in Parkinson’s Disease Patients

    A. Imarisio, J. Gervasoni, C. Marino, L. Santucci, E. Napolitano, T. Nuzzo, I. Yahyavi, M. Avenali, M. Cicchinelli, C. Galandra, M. Picascia, M. Grimaldi, C. Pacchetti, F. Errico, AM. D'Ursi, A. Urbani, A. Usiello, EM. Valente (Rome, Italy)

    Objective: We sought to identify a signature distinctive of Parkinson’s disease (PD) through two independent metabolomics approaches. Background: A recent meta-analysis showed a considerable inconsistency…
  • 2025 International Congress

    Levodopa mediated normalization of cerebello-thalamo-cortical GABA and Glutamate in Parkinson’s disease

    S. Prasad, D. Deelchand, M. Kumar, R. Yadav, P. Pal, J. Saini (Bengaluru, India)

    Objective: This study aims to evaluate the effect of levodopa on cerebello-thalamo-cortical (CTC) gamma-aminobutyric acid (GABA) and glutamate in patients with Parkinson’s disease (PD) using…
  • 2024 International Congress

    Effect of various mGlu2 and mGlu2/3 activators on parkinsonism: a sub-analysis in the MPTP-lesioned primate

    W. Kang, I. Frouni, S. Nuara, C. Kwan, J. Gourdon, D. Bédard, P. Huot (Montreal, Canada)

    Objective: To evaluate the effect of the metabotropic glutamate 2/3 (mGlu2/3) orthosteric activators (OAs) LY-354,740 and LY-404,039, as well as the effects of the metabotropic…
  • 2024 International Congress

    Untargeted Serum Metabolomics Identifies Glycine-Serine Metabolism Disruption as Biochemical Bignature in Parkinson’s Disease

    A. Imarisio, C. Marino, M. Avenali, G. Buongarzone, M. Picascia, T. Nuzzo, C. Gasparri, F. Errico, M. Grimaldi, MC. Monti, A. Filosa, M. Rondanelli, C. Pacchetti, AM. D'Ursi, A. Usiello, EM. Valente (Pavia, Italy)

    Objective: We attempted to identify a metabolomic signature distinctive of Parkinson’s disease (PD) through an untargeted metabolomics approach. Background: Using an high-performance liquid chromatography targeted…
  • 2024 International Congress

    the role of metabotropic glutamate receptors type 3 and 5 in parkinson’s disease: analysis of grm3 and grm5 genbe variants.

    M. Alborghetti, E. Bianchini, D. Rinaldi, I. de Bartolo, L. Di Menna, G. Battaglia, V. Bruno, T. Esposito, M. Borro, M. Simmaco, F. Pontieri, A. Berardelli, F. Nicoletti (Rome, Italy)

    Objective: The aim of the study was to examine the association between polymorphic variants of GRM3 and GRM5 and Parkinson’s disease (PD) and motor and…
  • 2024 International Congress

    Effect of the mGlu2 positive allosteric modulator biphenyl-indanone A on parkinsonian disability in the 6-hydroxydopamine-lesioned rat

    W. Kang, Y. Kulkarni, I. Frouni, C. Kwan, D. Bédard, P. Huot (Montreal, Canada)

    Objective: To evaluate the effect of biphenyl-indanone A (BINA), a metabotropic glutamate 2 (mGlu2) receptor positive allosteric modulator (PAM), on parkinsonian disability in the 6-OHDA-lesioned…
  • 2023 International Congress

    SLC1A7 mutation is a cause of the autosomal dominant form of Parkinson’s disease

    A. Kishore, M. Marc Sturm, F. Raimondi, P. Lichtner, A. Sreelatha, N. Casadei, C. Blauwendraat, G. Sarma, R. Kruger, A. Zimprich, A. Singleton, T. Gasser, O. Riess, M. Sharma (Kochi, India)

    Objective: To identify novel genes involved in the familial form of Parkinson’s disease (PD) in the Indian population. Background: Most of the familial forms of…
  • 2023 International Congress

    Investigating glutamate toxicity associated to Park2 mutations in pre-clinical models of Parkinson’s Disease

    I. Trezzi, M. Regoni, M. Magni, M. Schröter, A. Buccino, D. Lopez, G. Faustini, L. Murro, F. Biella, E. Frattini, R. Silipigni, M. Passafaro, A. Bellucci, M. Bortolozzi, J. Sassone, A. Di Fonzo (Milan, Italy)

    Objective: To generate and characterize induced pluripotent stem cells (iPSCs)-derived in vitro cellular models of Autosomal Recessive Juvenile Parkinsonism (ARJP) carrying Park2 mutations with a…
  • 2022 International Congress

    Synaptic Zn2+ Contribution to Parkinson’s Disease Pathophysiology: Pharmacological & Genetic Studies in Preclinical Mouse Models

    AM. Ouagazzal, J. Sikora (Marseille, France)

    Objective: The potential involvement of synaptic Zn2+ in development of Parkinson’s disease (PD) motor symptoms and dopaminergic neurodegeneration was investigated. Background: The progressive degeneration of…
  • 2022 International Congress

    Central fatigue and glutamatergic overactivity in Parkinson’s disease: possible impact of safinamide

    C. Pauletti, N. Locuratolo, D. Mannarelli, A. Maffucci, A. Petritis, F. Fattapposta (Rome, Italy)

    Objective: The aim of the present study was to test the hypothesis that central fatigue in Parkinson’s disease (PD) could be related to high levels…
  • 1
  • 2
  • 3
  • …
  • 5
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley